Abstract:Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is often already advanced or metastatic, resulting in poor treatment outcomes. Treatment of NSCLC mainly relies on surgery, radiation and chemotherapy, but the survival rate has not increased significantly in the past decade. Therefore, finding appropriate treatment methods is necessary and crucial. Radiotherapy (RT) is a frequently employed approach for tumor treatment and serves as the primary local treatment for NSCLC. However, it often results in a poor prognosis and severe side effects when administered at high-dose irradiation. Existing literature suggests that RT may trigger the expression of nuclear factor kappa B (NF-ΚB), potentially compromising its therapeutic efficacy. Consequently, the question remains: Can targeting NF-ΚB signaling enhance the sensitivity of RT in NSCLC Furthermore, studies have indicated that elevated levels of CXCR5 in NSCLC contribute to tumor growth. CXCR5 is situated upstream of the NF-ΚB pathway. As a result, it becomes imperative and indispensable to develop strategies targeting the CXCL13/CXCR5/NF-ΚB signaling axis to counteract NSCLC growth. Lenvatinib is a multi-kinase inhibitor targeted drug. It has been proven to inhibit VEGFR1-3, FGFR1-4 and PDGFR, inhibiting tumor growth. Lenvatinib has received clinical approval from the US FDA for the treatment of advanced hepatocellular carcinoma (HCC) and has been shown to inhibit NF-ΚB expression in HCC. However, the potential radiation-sensitizing mechanism of Lenvatinib in lung cancer remains unexplored. This study is dedicated to investigating the effects and molecular mechanisms of combining Lenvatinib with radiotherapy in NSCLC. Our results suggest that lenvatinib may enhance the sensitivity of NSCLC to RT. Furthermore, evidence from both the intrinsic and extrinsic apoptosis pathways (Caspase-3/Caspase-8/Caspase-9) and TUNEL experiments supports the idea that the combined treatment of lenvatinib with RT induces a more pronounced apoptotic response compared to individual treatments. Additionally, silencing CXCR5 in NSCLC also appears to enhance its responsiveness to RT. In our western blot (p-ATM, p-CHK2), flow cytometry (p-ATM), we showed that the combination of lenvatinib and RT may effective induce DNA damage. Our in vivo data demonstrates that the combination of Lenvatinib and RT exhibits superior tumor growth inhibition. Immunohistochemistry (IHC) staining of tumor tissue also revealed an upregulation of apoptosis-related proteins and the downregulation of CXCL13/CXCR5/NF-ΚB related proteins. In conclusion, our findings suggest that Lenvatinib can serve as a radiosensitizer, enhancing the sensitivity of NSCLC patients to radiotherapy by targeting the CXCL13/CXCR5/NF-ΚB signaling pathway. Citation Format: Tsai-Lan Liao, I-Tsang Chiang, Bo-Han Huang, Fei-Ting Hsu, Ming-Hsien Chan. Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 695.

Epoxymicheliolide Reduces Radiation‐Induced Senescence and Extracellular Matrix Formation by Disrupting NF‐κB and TGF‐β/SMAD Pathways in Lung Cancer

Capilliposide C From Lysimachia Capillipes Restores Radiosensitivity In Ionizing Radiation-Resistant Lung Cancer Cells Through Regulation Of Errfi1/Egfr/Stat3 Signaling Pathway

Downregulation of MMP-9 by epicatechin can improve the radiosensitivity of non-small cell lung cancer

Inhibition of LNC EBLN3P Enhances Radiation-Induced Mitochondrial Damage in Lung Cancer Cells by Targeting the Keap1/Nrf2/HO-1 Axis.

Β-Elemene Enhances Radiosensitivity in Non-Small-cell Lung Cancer by Inhibiting Epithelial–mesenchymal Transition and Cancer Stem Cell Traits Via Prx-1/NF-kB/iNOS Signaling Pathway

Β-Elemene Inhibits Tumor-Promoting Effect of M2 Macrophages in Lung Cancer.

Suppressing epithelial‐mesenchymal‐transition blue light therapy for reducing macrophage‐mediated cancerous pulmonary fibrosis: an in‐vitro study

Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer

Targeting senescence-like fibroblasts radiosensitizes non–small cell lung cancer and reduces radiation-induced pulmonary fibrosis

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

Exosomal miR‐196a‐5p enhances radioresistance in lung cancer cells by downregulating NFKBIA

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del

Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer.

Enhancement of Radiation Sensitivity by Erlotinib and Celecoxib in A549 Human Lung Cancer Cell Line

ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma

Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Radiation-Induced Lung Injury via miRNA-214-3p

Exposure of Breast and Lung Cancer Cells to a Novel Estrone Analog Prior to Radiation Enhances Bcl-2-Mediated Cell Death

Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity

Abstract 695: Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis

Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.